Foralumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CD3 epsilon |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Foralumab is a fully human monoclonal antibody that binds to CD3 epsilon.[1] Also called TZLS-401, it is currently in clinical development by Tiziana Life Sciences for treatment of Crohn's disease and other autoimmune diseases.[2] However foralumab did not show efficacy for Crohn's disease.[3]
It is currently in clinical development by Tiziana Life Sciences for treatment of secondary progressive Multiple sclerosis.[4][5]
References
- ↑ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103" (PDF). WHO Drug Information.
- ↑ "Foralumab". Tiziana Life Sciences plc.
- ↑ Giuffrida P, Di Sabatino A (September 2020). "Targeting T cells in inflammatory bowel disease". Pharmacological Research. 159: 105040. doi:10.1016/j.phrs.2020.105040. PMID 32585338. S2CID 220073839.
- ↑ Wexler M. "2nd SPMS Patient Sees Clinical Gains With Foralumab Treatment". Multiple Sclerosis News Today. Retrieved 16 June 2022.
- ↑ "Intranasal Foralumab Provides Neuroimaging and Clinical Improvements in Secondary Progressive Multiple Sclerosis". practicalneurology. Retrieved 6 August 2022.
This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.